A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-α in the treatment of advanced renal cell carcinoma or melanoma
- 31 December 1994
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (4), 530-532
- https://doi.org/10.1016/0959-8049(94)90433-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alphaEuropean Journal Of Cancer, 1992
- Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II studyEuropean Journal of Cancer and Clinical Oncology, 1991
- Disseminated Malignant Melanoma and Recombinant Interferon: Analysis of Seven Consecutive Phase II InvestigationsJournal of Investigative Dermatology, 1990
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- Interleukin-2: Inception, Impact, and ImplicationsScience, 1988
- In vivo anti‐tumor activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cellsInternational Journal of Cancer, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Reporting results of cancer treatmentCancer, 1981